Miezan T W, Dje N N, Doua F, Boa F
Projet de recherches cliniques sur la trypanosomiase, BP 1425 Daloa, Côte d'Ivoire.
Bull Soc Pathol Exot. 2002 Dec;95(5):362-5.
The treatment and post therapeutic follow up of patients diagnosed with HAT are important for HAT control. A longitudinal survey was implemented in the focus of Daloa (Côte d'Ivoire). A total of 812 patients infected with Trypanosoma brucei gambiense in meningoencephalitic stage and treated with melarsoprol were included, this study pointed out the biological characteristics of patients after treatment. The relapse occurs between 1 and 24 months after treatment. It is essentially neurological, and characterised by the presence in the CSF of antibodies, by the increase of cell count compared with value immediately after treatment, or by the presence of trypanosomes. The cure can be confirmed from 18 months after treatment, and is characterised by the absence of antibodies and trypanosomes in the CSF, by a normal cell count and a normal proteinorachy. Biological scares were recorded on some of the patients after 18 months of follow up, but no relapse occurred among them.
对确诊为非洲锥虫病(HAT)的患者进行治疗及治疗后的随访对控制HAT至关重要。在达洛亚(科特迪瓦)重点地区开展了一项纵向调查。共纳入812例处于脑膜脑炎阶段且接受美拉胂醇治疗的布氏冈比亚锥虫感染男性患者,该研究指出了患者治疗后的生物学特征。复发发生在治疗后1至24个月之间。主要为神经系统复发,其特征为脑脊液中出现抗体、与治疗后即刻的值相比细胞计数增加或存在锥虫。治疗18个月后可确认治愈,其特征为脑脊液中无抗体和锥虫、细胞计数正常且蛋白/脑脊液正常。随访18个月后,部分患者记录到生物学恐慌,但其中无复发情况。